Literature DB >> 31565223

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Satoshi Fujii1, Takayuki Yoshino2, Kentaro Yamazaki3, Kei Muro4, Kensei Yamaguchi5, Tomohiro Nishina6, Satoshi Yuki7, Eiji Shinozaki5, Kohei Shitara2, Hideaki Bando4, Sachiyo Mimaki8, Chikako Nakai9, Koutatsu Matsushima9, Yutaka Suzuki10, Kiwamu Akagi11, Takeharu Yamanaka12, Shogo Nomura13, Hiroyasu Esumi14, Masaya Sugiyama15, Nao Nishida15, Masashi Mizokami15, Yasuhiro Koh16, Yukiko Abe9, Atsushi Ohtsu17, Katsuya Tsuchihara8.   

Abstract

To enable the widespread application of genomic medicine, the extraction of genomic DNA from thin sections of archived formalin-fixed and paraffin-embedded (FFPE) tissue blocks for next-generation sequencing (NGS) is often necessary. However, there are currently no guidelines available on which specific regions of the microtome sections to use for macrodissection with respect to the histopathological factors observed under microscopic examination. The aim of this study was to clarify the relationship between histopathological factors and DNA quality, and to standardize the macrodissection method for more efficient implementation of NGS. FFPE tissue specimens of 218 patients from the Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics study were used to investigate the relationship between 15 histopathological factors and the quantitative ratio of double-stranded DNA (dsDNA) to total nucleic acids, as well as the ∆ crossing point value of each tissue specimen. Multivariate logistic regression analysis revealed that specimen storage of ≥3 years was negatively associated with dsDNA quality (P=0.0007, OR: 4.30, 95% CI: 1.85-10.04). In contrast, the presence of a mucus pool was positively associated with dsDNA quality (P=0.0308, OR: 0.23, 95% CI: 0.06-0.87). Metastatic tumors and longer specimen storage periods were significantly associated with lower ∆Cp values (P=0.0007, OR: 4.43, 95% CI: 1.87-10.49; and P=0.0003, OR: 5.51, 95% CI: 2.18-13.95, respectively). Therefore, macrodissection should not be performed on specimens exhibiting histopathological factors associated with poor DNA quality. In particular, the use of tissue blocks with a storage period of <3 years allows the extraction of genomic DNA suitable for NGS.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  dsDNA; formalin-fixed and paraffin-embedded tissue specimen; histopathological factors; next-generation sequencing; ∆Cp

Year:  2019        PMID: 31565223      PMCID: PMC6759515          DOI: 10.3892/br.2019.1235

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  11 in total

1.  A straightforward assay to evaluate DNA integrity and optimize next-generation sequencing for clinical diagnosis in oncology.

Authors:  Fabiana Bettoni; Fernanda Christtanini Koyama; Paola de Avelar Carpinetti; Pedro Alexandre Favoretto Galante; Anamaria Aranha Camargo; Paula Fontes Asprino
Journal:  Exp Mol Pathol       Date:  2017-11-21       Impact factor: 3.362

2.  Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine.

Authors:  Seokhwi Kim; Charny Park; Yongick Ji; Deok G Kim; Hyunsik Bae; Michael van Vrancken; Duk-Hwan Kim; Kyoung-Mee Kim
Journal:  J Mol Diagn       Date:  2016-11-10       Impact factor: 5.568

3.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

4.  FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.

Authors:  Amanda L Treece; Nathan D Montgomery; Nirali M Patel; Chris J Civalier; Leslie G Dodd; Margaret L Gulley; Jessica K Booker; Karen E Weck
Journal:  Cancer Cytopathol       Date:  2016-02-16       Impact factor: 5.284

5.  Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.

Authors:  Catherine I Dumur; Jorge A Almenara; Celeste N Powers; Andrea Ferreira-Gonzalez
Journal:  Diagn Pathol       Date:  2015-09-17       Impact factor: 2.644

6.  Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.

Authors:  Silvia Bonfiglio; Irene Vanni; Valeria Rossella; Anna Truini; Dejan Lazarevic; Maria Giovanna Dal Bello; Angela Alama; Marco Mora; Erika Rijavec; Carlo Genova; Davide Cittaro; Francesco Grossi; Simona Coco
Journal:  BMC Cancer       Date:  2016-08-30       Impact factor: 4.430

7.  Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.

Authors:  Minho Cho; Soomin Ahn; Mineui Hong; Heejin Bang; Michael Van Vrancken; Seungtae Kim; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Jong-Mu Sun; Se Hoon Lee; Myung-Ju Ahn; Keunchil Park; Duk Hwan Kim; Seunggwan Lee; Woongyang Park; Kyoung-Mee Kim
Journal:  Oncotarget       Date:  2017-06-27

8.  Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation.

Authors:  Naoki Einaga; Akio Yoshida; Hiroko Noda; Masaaki Suemitsu; Yuki Nakayama; Akihisa Sakurada; Yoshiko Kawaji; Hiromi Yamaguchi; Yasushi Sasaki; Takashi Tokino; Mariko Esumi
Journal:  PLoS One       Date:  2017-05-12       Impact factor: 3.240

9.  Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue.

Authors:  Danielle Mercatante Carrick; Michele G Mehaffey; Michael C Sachs; Sean Altekruse; Corinne Camalier; Rodrigo Chuaqui; Wendy Cozen; Biswajit Das; Brenda Y Hernandez; Chih-Jian Lih; Charles F Lynch; Hala Makhlouf; Paul McGregor; Lisa M McShane; JoyAnn Phillips Rohan; William D Walsh; Paul M Williams; Elizabeth M Gillanders; Leah E Mechanic; Sheri D Schully
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

10.  Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Authors:  Eiji Shinozaki; Takayuki Yoshino; Kentaro Yamazaki; Kei Muro; Kensei Yamaguchi; Tomohiro Nishina; Satoshi Yuki; Kohei Shitara; Hideaki Bando; Sachiyo Mimaki; Chikako Nakai; Koutatsu Matsushima; Yutaka Suzuki; Kiwamu Akagi; Takeharu Yamanaka; Shogo Nomura; Satoshi Fujii; Hiroyasu Esumi; Masaya Sugiyama; Nao Nishida; Masashi Mizokami; Yasuhiro Koh; Yukiko Abe; Atsushi Ohtsu; Katsuya Tsuchihara
Journal:  Br J Cancer       Date:  2017-10-03       Impact factor: 7.640

View more
  1 in total

1.  The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.

Authors:  Yutaka Hatanaka; Takeshi Kuwata; Eiichi Morii; Yae Kanai; Hitoshi Ichikawa; Takashi Kubo; Kanako C Hatanaka; Kazuko Sakai; Kazuto Nishio; Satoshi Fujii; Wataru Okamoto; Takayuki Yoshino; Atsushi Ochiai; Yoshinao Oda
Journal:  Pathol Int       Date:  2021-10-06       Impact factor: 2.121

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.